Amgen Inc. (NASDAQ:AMGN) Holdings Boosted by Choreo LLC

Choreo LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,851 shares of the medical research company’s stock after acquiring an additional 180 shares during the period. Choreo LLC’s holdings in Amgen were worth $1,109,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AMGN. Balboa Wealth Partners bought a new stake in shares of Amgen during the third quarter valued at approximately $254,000. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Amgen by 8.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 120,005 shares of the medical research company’s stock valued at $32,253,000 after buying an additional 9,106 shares during the last quarter. Clear Creek Financial Management LLC bought a new stake in shares of Amgen during the third quarter valued at approximately $215,000. Mayfair Advisory Group LLC bought a new stake in shares of Amgen during the third quarter valued at approximately $243,000. Finally, Crescent Sterling Ltd. raised its holdings in shares of Amgen by 2.0% during the third quarter. Crescent Sterling Ltd. now owns 9,451 shares of the medical research company’s stock valued at $2,540,000 after buying an additional 187 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $329.00 price objective on shares of Amgen in a research note on Wednesday, April 3rd. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. UBS Group lowered their price objective on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Finally, Raymond James assumed coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating on the stock. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $297.40.

Amgen Trading Down 0.9 %

Shares of NASDAQ:AMGN opened at $273.94 on Wednesday. The firm has a fifty day moving average of $274.76 and a two-hundred day moving average of $281.37. The firm has a market capitalization of $146.94 billion, a P/E ratio of 21.93, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same quarter in the previous year, the business earned $4.09 EPS. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. On average, equities analysts expect that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.29%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.